Estamos no ar no ! Saiba mais

Stoke Therapeutics

STOK

Valor de mercado US$ 1,56 bi

24,17 USD

-0,44

1,79%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

24,17

0,00

0%

1 dia

-1,79%

5 dias

-1,95%

1 mês

-13,4%

3 meses

-16,97%

6 meses

-31,61%

No acumulado do ano

-21,78%

1 ano

-29,27%

5 anos

6,71%

10 anos

-5,48%

Sobre: Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Funcionários: 170

Saúde Biotecnologia

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 17,6%

Neutro 76,5%

Negativo 5,9%

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on October 15, 2026, it granted stock options to purchase shares of common stock to Stephen Aschettino, the Com.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced two presentations of data for STK-002 at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, taking place October 9-12 in New Orleans. STK-002 represents a novel approach to Autosomal Dominant Optic Atrophy (ADOA), the most common inherited optic nerve disorder, by targeting.

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced two presentations of data for STK-002 at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, taking place October 9-12 in New Orleans. STK-002 is an investigational medicine designed to target the underlying cause of Autosomal Dominant Optic Atrophy (ADOA) by increasing OPA1.

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced the completion of a successful meeting with the U.S. Food and Drug Administration (FDA) intended to align on key aspects of the.

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced the appointment of Bo Cumbo to its Board of Directors. Concurrent with Mr. Cumbo's appointment, Edward Kaye, M.D., has retired.

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on September 15, 2026, it granted stock options to purchase an aggregate of 53,175 shares of common stock to ni.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics to Present at the Cantor Global Healthcare Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Cantor Global Healthcare C.

Stoke Therapeutics to Present at the Cantor Global Healthcare Conference

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on August 17, 2026, it granted stock options to purchase an aggregate of 70,950 shares of common stock to seven.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics' Dravet Trial Tops Enrollment Target With Zero Dropouts

Stoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR study of zorevunersen for Dravet syndrome has enrolled 162 patients, exceeding its target enrollment of 150, with no patient discontinuations reported to date.

Stoke Therapeutics' Dravet Trial Tops Enrollment Target With Zero Dropouts

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

Stoke Therapeutics remains a "Buy," driven by progress on zorevunersen for SCN1A Dravet Syndrome and robust clinical milestones ahead. The company expects an FDA meeting in H2 2026, rolling NDA submission in Q1 2027, and phase 3 EMPEROR data in Q3 2027 for zorevunersen. The advancement of STK-002 for autosomal dominant optic atrophy in the phase 1 OSPREY study showcases the TANGO platform's broader therapeutic potential.

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™